scPharmaceuticals Inc. (SCPH)
5.67
0.00 (0.00%)
Inactive · Last trade price on Oct 6, 2025
scPharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -91.72 | -85.15 | -54.81 | -36.84 | -28.03 | -32.21 |
Depreciation & Amortization | 0.02 | 0.02 | 0.02 | 0.04 | 0.44 | 0.4 |
Stock-Based Compensation | 5.33 | 5.44 | 4.86 | 2.84 | 2.37 | 2 |
Other Adjustments | 11.19 | 22.24 | -2.99 | -0.26 | 0.68 | 0.67 |
Change in Receivables | -13.35 | -7.29 | -4.49 | - | - | - |
Changes in Inventories | 0.55 | -5.16 | -7.61 | -1.23 | - | - |
Changes in Accounts Payable | 6 | 0.59 | 5.56 | 1.77 | -2.37 | 1.21 |
Changes in Other Operating Activities | -0.07 | -1.23 | 0.22 | -0.89 | -0.23 | 0.24 |
Operating Cash Flow | -65.86 | -70.54 | -59.24 | -34.58 | -27.15 | -27.69 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Capital Expenditures | - | -0.02 | -0.04 | -0.02 | -0.01 | - |
Purchases of Investments | - | - | -50.6 | -67.54 | -9.01 | -72.16 |
Proceeds from Sale of Investments | - | 29.32 | 70.6 | 21.7 | 41.15 | 38.7 |
Investing Cash Flow | - | 29.3 | 19.97 | -45.86 | 32.13 | -33.46 |
Financing Activities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Long-Term Debt Issued | - | 46.77 | - | 47.3 | - | - |
Long-Term Debt Repaid | - | -50 | - | -17.5 | -2.5 | - |
Net Long-Term Debt Issued (Repaid) | - | -3.23 | - | 29.8 | -2.5 | - |
Issuance of Common Stock | - | 54.23 | 14.85 | 47.98 | 0.05 | 61.31 |
Repurchase of Common Stock | - | -0.17 | - | -0.05 | -0.08 | -0.16 |
Net Common Stock Issued (Repurchased) | - | 54.06 | 14.85 | 47.93 | -0.03 | 61.15 |
Other Financing Activities | - | 19.25 | - | -0.5 | - | -0.8 |
Financing Cash Flow | 68.19 | 70.08 | 14.85 | 77.23 | -2.53 | 60.35 |
Net Cash Flow
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Cash Flow | 2.31 | 28.84 | -24.43 | -3.21 | 2.45 | -0.81 |
Beginning Cash & Cash Equivalents | 38.5 | 46.81 | 71.24 | 74.45 | 72 | 72.81 |
Ending Cash & Cash Equivalents | 40.81 | 75.66 | 46.81 | 71.24 | 74.45 | 72 |
Free Cash Flow
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Free Cash Flow | -65.86 | -70.56 | -59.28 | -34.6 | -27.16 | -27.69 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -131.80% | -194.21% | -436.14% | - | - | - |
Free Cash Flow Per Share | -1.27 | -1.58 | -1.54 | -1.22 | -0.99 | -1.13 |
Levered Free Cash Flow | -85.22 | -94.18 | -56.66 | -7.37 | -32.7 | -30.36 |
Unlevered Free Cash Flow | -60.04 | -70.58 | -57.24 | -36.49 | -27.99 | -28.09 |